Abstract
ContextAdipokines are linked to the development of cardiovascular dysfunction in type 2 diabetes (DM2). In DM2-patients, circulating levels of omentin-1, an adipokine preferentially expressed in epicardial adipose tissue, are decreased. This study investigated whether omentin-1 has a cardioprotective function.MethodsOmentin-1 levels in plasma and cardiac fat depots were determined in DM2-patients versus controls. Moreover, the relation between omentin-1 levels and cardiac function was examined in men with uncomplicated DM2. Finally, we determined whether omentin-1 could reverse the induction of cardiomyocyte dysfunction by conditioned media derived from epicardial adipose tissue from patients with DM2.ResultsOmentin-1 was highly expressed and secreted by epicardial adipose tissue, and reduced in DM2. Circulating omentin-1 levels were lower in DM2 versus controls, and positively correlated with the diastolic parameters early peak filling rate, early deceleration peak and early deceleration mean (all P<0.05). The improved diastolic function following pioglitazone treatment associated with increases in omentin-1 levels (P<0.05). In vitro, exposure of cardiomyocytes to conditioned media derived from epicardial adipose tissue from patients with DM2 induced contractile dysfunction and insulin resistance, which was prevented by the addition of recombinant omentin.ConclusionThese data identify omentin-1 as a cardioprotective adipokine, and indicate that decreases in omentin-1 levels could contribute to the induction of cardiovascular dysfunction in DM2.
Highlights
Cardiac dysfunction and myocardial insulin resistance are common in patients with type 2 diabetes (DM2) [1,2]
We examined whether omentin-1 expression and secretion in various adipose tissue depots, including epicardial adipose tissue (EAT), pericardial, and subcutaneous adipose tissue, is altered in patients with DM2
We evaluated whether omentin1 levels were associated with metabolic and cardiac parameters in men with uncomplicated DM2 before and after intervention with the insulin-sensitizing drug pioglitazone, which is known to act predominantly on adipose tissue and was shown to improve cardiac diastolic function in this cohort [20,21]
Summary
Cardiac dysfunction and myocardial insulin resistance are common in patients with type 2 diabetes (DM2) [1,2]. Omentin-1 is an adipokine with decreased circulating levels in conditions associated with insulin resistance [7,8,9,10,11,12]. Omentin-1 enhances insulin-mediated stimulation of Aktphosphorylation, glucose uptake and inhibits tumor necrosis factor a-induced inflammation [15,16]. This indicates that omentin-1, like adiponectin, may act as a protective adipokine
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
